



AGENDA



The Role of Cognizin in Enhancing Focus and Attention

- Citicoline Overview
- · Citicoline Metabolism and MoA - How does citicoline work?
- Citicoline Human Studies
 Potential as Nootropic

5


TRENDS IN COGNITIVE HEALTH: SUPPLEMENTS **KYOWA** Brain Supplement Sales and Growth • In 2020, the brain health market grew to a \$1 billion value. The pandemic effect set the market up for post-pandemic growth, and projections now show an 8.1% gain for 2022.

What is Citicoline?



- A mononucleotide comprising cytosine, ribose, pyrophosphate and choline.
- An endogenous intermediate in the biosynthesis of structural membrane phospholipids, and Acetylcholine, a nerve system activator.

- Citicoline



Application

USA: Dietary Supplement, Food/Beverage (GRAS)

EU: Dietary Supplement (Novel Food)

Japan: Pharmaceutical
 China: Pharmaceutical (as sodium salt)

7

AGENDA




- · Citicoline Overview
- Citicoline Metabolism and MoA
 - How does citicoline work?
- · Citicoline Human Studies
 - Potential as Nootropic


8


How Does Citicoline Work?






- Citicoline metabolizes to raise Acetylcholine levels and provide Phospholipid support
- Citicoline exists in our cells and is specifically critical for optimal brain cell performance.
 Citicoline is sourced for multiple Phospholipids which is a brain nutrient to consist of brain cell membrane.
- Citicoline also supports
 Neurotransmitters, the way
 our brain cells communicate,
 to activate the nerves system.







Citicoline Overview Citicoline Metabolism and MoA How does citicoline work? Citicoline Human Studies Potential as Nootropic



KYOWA Cognizin® Citicoline Human Studies Cognizin® Citicoline Increases Energy in Brain **β-NTP** levels 16 physically and mentally healthy individuals (8M and 8F, 47.3 \pm 5.4 y, BMI = 25.3 \pm 5.2) Citicoline 500 mg or 2000 mg/day (n = 8 each) 140 130 · Dose: 120 Term:
Index: 6 wks Measurement of β-NTP as cellular energy by 31P-MRS in the frontal lobe; Anterior Cingulate Cortex (ACC) 110 of baseline 90 % 80 80 ACC: area responsible for focus, attention, concentration 60 * Significant changes from baseline Silveri MM et al., NMR in Biomedicine. 21(10): 1066-75, 200

Cognizin® Citicoline Studies **KYOWA** Cognizin® Citicoline Increases Phospholipid Synthesis (observed in humans) Oral citicoline supplementation increased phospholipids synthesis in brain. - Subjects: 16 physically and mentally healthy individuals (8M and 8F, $47.3\pm5.4~\text{y})$ 140 130 Dose: Citicoline 500 mg or 2,000 mg/day(n=8 each) 120 110 100 % of baseline Term: Index: Membrane phospholipids in frontal lobe (ACC) measured by ³¹P-MRS; PE (anabolite) and GPE (catabolite) 90 80 ACC: Anterior cingulate cortex PE: Phosphoethanolamine GPE: Glycerophosphosethanolamine PE levels GPE levels






Cognizin® Citicoline Human Studies

Cognizin® Citicoline Improves Motor Speed and Attention in Adolescents

Design: Randomized, placebo controlled, double blinded study
Subjects: Healthy adolescent males (N=75, 13-18 yo.)
Dose: Citicoline (N=51, 250 or 500 mg/day) or Placebo (N=25)
Term: 28 days
Measurements: Finger tap test, Ruff 287 selective attention test MOSES interview (Side effects)

Table 1. Baselve Demographe Charasteriatics—Between-Group Differences.

Treatment (n = 51) Placebo (n = 26) p
Age ± 50 15 41 ± 1.70 15.71 ± 1.72 0.98
Besterion (years) ± 50 15 41 ± 1.70 15.71 ± 1.72 0.98
Height (nn) ± 50 90 ± 1.76 90 ± 1.82 0.68
Height (nn) ± 50 171 ± 1.92 0.98
Height (nn) ± 50 0.90 ± 1.95 0.90 ± 1.



Cognizin® Citicoline Human Studies

Cognizin® Citicoline improves motor speed and attention in adolescents


Ruff 2&7 selective attention test


Cross out as many 2 & 7 per timed interval for a total of 5 minutes

1 8 9 2 5 4 7 1 5 4 6 6 9 2 3 7 3 5 8 6 5 9 6 3 3 3 6 4 7 9 8 0 5 8 6 3 7 8 2 2 9 5 8 1 6 9 3 4 9 7 8 2 9 8 4 4 1 9 8 2 0

Placebo Cognizin

Cognizin® Citicoline Human Studies Cognizin® Citicoline Improves Memory Design: Randomized placebo-controlled parallel, double-bind study Subjects: Healthy male/female age 50-85 years with AAMI* Dose: Citicoline 500 mg/day (two-piece capsule) or placebo Term: 12 weeks Outcome: Cognitive test battery, which includes 7 tests *Age-associated memory impairment (AAMI). In order to investigate citicoline efficacy for memory properly, screened healthy subjects who have no health conditions that would prevent from fulfilling the study requirements but complaint or self-report memory loss. NIH has proposed criteria for defining AAMI: (1) Males and females at least 50 years old (2) Complaints of memory loss and memory test performance that is at least 1 standard deviation (SD) below the mean established for young adults on a standardized test (3) Evidence of adequate intellectual function A Mate 21 August 2001; 2155-2160





23

Cognizin® Citicoline Human Studies **KYOWA** Cognizin® Citicoline Improves Memory Composite memory, calculated using the scores of 4 memory tests*, also significantly improved. Composite Memory 40 <u>e</u> 30 • Conclusion Baselir 20 Dietary supplementation of citicoline for 12-week improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. Change of Score from 0 -10 Pla ceb o Citicoline "To avoid "cherry picking", shown in the FDA guidan it is appropriate To combine several tests into a single variable To account for multiplicity. Data showed as LS mean +/- SEM. ANCOVA was used to assess differences between test groups. "P<0.00625, due to adjustment of multiplicity (error correction) using the Bonferroni correction. -30

